$ABVX News

Truist Securities Maintains Buy on Abivax, Lowers Price Target to $135

Jefferies Downgrades Abivax to Hold, Lowers Price Target to $90

Morgan Stanley Maintains Overweight on Abivax, Lowers Price Target to $132

Abivax: M&A Premium Vanishes After Obefazimod Phase 3 Safety Signal

Wedbush Upgrades Abivax to Neutral, Lowers Price Target to $90

Citizens Maintains Market Outperform on Abivax, Raises Price Target to $187

Why Is Abivax Stock Sinking Tuesday?

BTIG Reiterates Buy on Abivax, Maintains $150 Price Target

Citizens Reiterates Market Outperform on Abivax, Maintains $131 Price Target

Abivax Repurchases Royalty Certificates For $90M And Prices $45M Offering Of 403,347 ADS At $111.57 Per Share

Abivax: Going It Alone At A Premium (Rating Downgrade)

Barclays Maintains Overweight on Abivax, Raises Price Target to $148

Abivax Announces Full Year 2025 Financial Results and Provides Business Updates

Abivax shares are trading higher after Jefferies initiated its coverage on the stock with a Buy rating and announced a price target of $160.

Abivax shares are trading higher after Jefferies initiated its coverage on the stock with a Buy rating and announced a price target of $160.

Jefferies Initiates Coverage On Abivax with Buy Rating, Announces Price Target of $160

AstraZeneca Abivax Talks Highlight Biotech Expansion And Valuation Upside Potential

Is The Market Getting Ahead Of Itself On ABIVAX (ENXTPA:ABVX) After Multi‑Year Surge

Abivax Pushes Back On Takeover Rumors

BTIG Reiterates Buy on Abivax, Maintains $150 Price Target